newsfilter
← Latest News
Business Wire·

Epizyme Announces Data from TAZVERIK® (Tazemetostat) Clinical Programs to be Presented During Poster Sessions at 2021 ESMO Virtual Congress

Two Poster Presentations for Tazemetostat, a Methyltransferase Inhibitor, in Metastatic Castration-Resistant Prostate Cancer and in Combinations in Patients with Solid Tumors Epizyme, Inc. (NASDAQ:EPZM), a fully integrated, commercial-stage bioph